Literature DB >> 33742341

Blinatumomab to improve the outcome of children with relapsed B-cell acute lymphoblastic leukemia.

J L Fuster1, F Bautista2, B González3, J M Fernández4, S Rives5, J L Dapena5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33742341     DOI： 10.1007/s12094-021-02590-0

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


× No keyword cloud information.
  5 in total

1.  Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment.

Authors:  C Eckert; N Hagedorn; L Sramkova; G Mann; R Panzer-Grümayer; C Peters; J-P Bourquin; T Klingebiel; A Borkhardt; G Cario; J Alten; G Escherich; K Astrahantseff; K Seeger; G Henze; A von Stackelberg
Journal:  Leukemia       Date:  2015-03-09       Impact factor: 11.528

2.  Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

Authors:  Franco Locatelli; Gerhard Zugmaier; Carmelo Rizzari; Joan D Morris; Bernd Gruhn; Thomas Klingebiel; Rosanna Parasole; Christin Linderkamp; Christian Flotho; Arnaud Petit; Concetta Micalizzi; Noemi Mergen; Abeera Mohammad; William N Kormany; Cornelia Eckert; Anja Möricke; Mary Sartor; Ondrej Hrusak; Christina Peters; Vaskar Saha; Luciana Vinti; Arend von Stackelberg
Journal:  JAMA       Date:  2021-03-02       Impact factor: 56.272

3.  Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

Authors:  Patrick A Brown; Lingyun Ji; Xinxin Xu; Meenakshi Devidas; Laura E Hogan; Michael J Borowitz; Elizabeth A Raetz; Gerhard Zugmaier; Elad Sharon; Melanie B Bernhardt; Stephanie A Terezakis; Lia Gore; James A Whitlock; Michael A Pulsipher; Stephen P Hunger; Mignon L Loh
Journal:  JAMA       Date:  2021-03-02       Impact factor: 56.272

4.  Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study.

Authors:  Franco Locatelli; Gerhard Zugmaier; Noemi Mergen; Peter Bader; Sima Jeha; Paul-Gerhardt Schlegel; Jean-Pierre Bourquin; Rupert Handgretinger; Benoit Brethon; Claudia Rossig; Christiane Chen-Santel
Journal:  Blood Cancer J       Date:  2020-07-24       Impact factor: 11.037

5.  Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia.

Authors:  Julie A E Irving; Amir Enshaei; Catriona A Parker; Rosemary Sutton; Roland P Kuiper; Amy Erhorn; Lynne Minto; Nicola C Venn; Tamara Law; Jiangyan Yu; Claire Schwab; Rosanna Davies; Elizabeth Matheson; Alysia Davies; Edwin Sonneveld; Monique L den Boer; Sharon B Love; Christine J Harrison; Peter M Hoogerbrugge; Tamas Revesz; Vaskar Saha; Anthony V Moorman
Journal:  Blood       Date:  2016-05-26       Impact factor: 22.113
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.